The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 21, 2023

Filed:

Oct. 01, 2020
Applicant:

Medimmune, Llc, Gaithersburg, MD (US);

Inventors:

Nabendu Pore, Gaithersburg, MD (US);

Martin J. Borrok, III, Gaithersburg, MD (US);

Emil F. Michelotti, Gaithersburg, MD (US);

David A. Tice, Gaithersburg, MD (US);

Robert E. Hollingsworth, Gaithersburg, MD (US);

Chien-Ying Chang, Gaithersburg, MD (US);

Partha Chowdhury, Gaithersburg, MD (US);

Assignee:

MedImmune, LLC, Gaithersburg, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 47/6803 (2017.08); A61K 47/6811 (2017.08); A61K 47/6825 (2017.08); A61K 47/6831 (2017.08); A61K 47/6849 (2017.08); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/524 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.


Find Patent Forward Citations

Loading…